In their interesting article, Ashraf et al 1 presented a modifying of the current treatment protocols for central retinal vein occlusion (CRVO). We want to address some issues directly related to the ...

June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Recent media reports from Pakistan suggest that Imran Khan, the former Prime Minister and World Cup-winning captain, has reportedly lost nearly 85% of vision in his right eye due to central retinal ...

CHICAGO -- A novel antibody-biopolymer conjugate (ABC) achieved visual acuity comparable to aflibercept (Eylea) for retinal vein occlusion (RVO) with less frequent dosing, according to a randomized ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Vabysmo achieved positive safety and efficacy results in ...

‒ Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept – ‒ More Vabysmo patients showed an absence of blood ...

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Genentech has initiated two phase 3 trials investigating ...